Self ‐Therapeutic Nanoparticle That Alters Tau Protein and Ameliorates Tauopathy Toward a Functional Nanomedicine to Tackle Alzheimer's

Pathogenic tau triggers tauopathy, which serves as a focal point for many other neurodegenerative diseases. Nanogold polyethylene glycol(Au ‐PEG) alters tau as a nanochaperon and lowers protopathic tau burden while also acting as kinetic stabilizer preventing tau oligomerization. Au‐PEG inhibits amyloidosis in human AD serum by remodeling tau‐like pro‐dementia factors. Editing tau function by Au‐PEG brings optimism to managing Alzheimer's dementia. AbstractTauopathy is a complex disorder associated at the junction of several other pathologies. Intrinsically disordered tau protein remains therapeutically challenging due to its undruggable nature and is a possible reason for monumental failure of several tau ‐based therapies. Herein, nanogold remodeled tau is reported as a pseudo‐nanochaperon and shows therapeutic benefit by passive targeting in transgenic tau P301L mutant mice. Treatment with nanogold polyethylene glycol (Au‐PEG) conjugate moderately improves the learning ability of the tau P301L mice that corroborates with diminished phosphorylated tau burden. Circulating total tau level that acts in a prion fashion is significantly reduced upon Au‐PEG treatment. Similarly, a high level of tau is found in macaque monkey serum and Au‐PEG inhibits amyloidosis of Alzheimer's patients and primate's serum samples ex vivo. Addtionally, brain MRI of an old aged macaque monkey shows the decrease of grey matter, which correlates with mutual loss of grey matter upon...
Source: Small - Category: Nanotechnology Authors: Tags: Communication Source Type: research